Insulet Corporation
PODDInsulet Corporation (PODD) develops advanced insulin management systems, most notably its Omnipod insulin management system. The company focuses on innovative healthcare solutions for people with insulin-dependent diabetes, offering tubeless, wearable devices that provide continuous insulin delivery and improve quality of life. Founded in 2000, Insulet is headquartered in Massachusetts and is known for its commitment to enhancing diabetes care through user-friendly and technology-driven products.
Company News
BVI announced the appointment of Jim Hollingshead as President & CEO, succeeding Shervin Korangy. Hollingshead brings over 20 years of medical device experience from leadership roles at Insulet and ResMed. BVI has expanded its ophthalmic portfolio with FDA approvals for premium IOLs and new surgical platforms, positioning itself as a challenger i...
Tandem Diabetes Care reported a Q2 loss of $0.78 per share, missed earnings estimates, and announced a voluntary medical device correction for t:slim X2 insulin pumps due to potential speaker-related issues affecting insulin delivery.
Insulet reported strong Q2 earnings, beating estimates with $649.1 million in revenue, and raised its full-year sales guidance to $2.57-$2.63 billion, driven by increased adoption of its Omnipod 5 insulin pump technology.
The global diabetes care devices market is projected to grow from $33.58 billion in 2024 to $76.44 billion by 2034, driven by increasing diabetes cases, technological advancements, and rising awareness of diabetes management tools.
Several healthcare and AI-driven companies are demonstrating significant potential in transforming medical technologies, offering innovative therapies and solutions across various medical domains like gene editing, telehealth, and precision medicine.
